Menu Back toSession 4: Addressing Common Challenges— Registration and IRB Reviews

Master Protocol Workshop

Session 4: Addressing Common Challenges— Registration and IRB Reviews

Session Chair(s)

Michelle  Detry, PhD

Michelle Detry, PhD

  • Director, Adaptive Trial Execution & Senior Statistical Scientist
  • Berry Consultants LLC, United States
AnnCatherine M. Downing, PharmD

AnnCatherine M. Downing, PharmD

  • Chief Operating Officer - Lilly Research Laboratories
  • Eli Lilly and Company, United States
Master Protocols may not fit the standard methods for trial registration or IRB review. This session will have presentations on the unique considerations for registering a Master Protocol on and submitting for IRB reviews. The registering and review of these innovative designs may require additional interactions to determine registration requirements or educational materials for IRBs unfamiliar with Master Protocols.
Learning Objective :
  • Explain the standard approach for registering a trial on and how Master Protocols may differ
  • Outline strategies for submissions to IRBs to facilitate an informed and timely review process for these innovative protocols
  • Obtain suggestions for interacting with the and IRB teams and how the interactions and estimated timelines may be different from standard trials


Heather  Dobbins, PhD

Addressing Common Challenges: IRB Review

Heather Dobbins, PhD

  • Lead Results Analyst, NCBI/NLM
  • National Institutes of Health (NIH), United States
Lindsay  McNair, MD, MPH, MS


Lindsay McNair, MD, MPH, MS

  • Chief Medical Officer
  • WCG, United States